Zhenyuan (Marius) Zhou
About Zhenyuan (Marius) Zhou
Zhenyuan (Marius) Zhou is an Associate Director Clinician at BeiGene and an Attending Physician at Yosemite Clinic & Hospital in Shanghai, China, with extensive experience in clinical trials and therapeutic research.
Associate Director Clinician at BeiGene
Zhenyuan (Marius) Zhou currently holds the position of Associate Director Clinician at BeiGene in Shanghai, China. In this role, he is involved in various clinical operations and research activities, leveraging his extensive experience in medical research and clinical trials, particularly in the autoimmune and rare disease sectors.
Previous Roles at Pfizer
Before joining BeiGene, Zhenyuan (Marius) Zhou worked for Pfizer in Shanghai, China, where he held several notable positions. He started as a Senior Manager Clinician from 2018 to 2021, a position he held for three years. He then briefly served as Associate Director in 2021. During his tenure, he contributed to various clinical research projects and trials, further establishing his expertise in the field.
Attending Physician at Yosemite Clinic & Hospital
Currently, Zhenyuan (Marius) Zhou also serves as an Attending Physician at Yosemite Clinic & Hospital (上海优仕美地医疗) in Shanghai, China. His role involves direct patient care, with a focus on rheumatology and clinical immunology. This position allows him to apply his clinical skills and medical knowledge in a hands-on healthcare setting.
Educational Background
Zhenyuan (Marius) Zhou has an extensive educational background, having studied at Shanghai Jiao Tong University. He earned a Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from 2002 to 2007, followed by a Master of Science (MS) in Internal Medicine from 2009 to 2012. He further specialized by obtaining a Doctor of Philosophy (PhD) in Rheumatology from 2012 to 2015. His academic achievements have laid a solid foundation for his medical and research career.
Expertise in Therapeutic Research and Clinical Trials
Zhenyuan (Marius) Zhou possesses significant expertise in early discovery and research aimed at identifying new therapeutic targets and modalities, such as PROTAC/CDAC and iADC. He has also been involved in iPSC and CAR-T / NK therapies. His experience includes conducting Phase 1 to Phase 3 clinical trials for autoimmune and rare diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), myositis, rheumatoid arthritis, and vasculitis. This experience highlights his diverse skill set and commitment to advancing medical science.